Physician profile
Jonathan Parrack
NPI 1043453046
$2,538.06
in general payments reported to CMS, 2019-2025
28 companies · $1,160 in 2025
The $1,160 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $161 · 2020: $172 · 2021: $223 · 2022: $140 · 2023: $168 · 2024: $514 · 2025: $1,160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,842.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,842.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $826.48 | 2019-2025 | |
| Qol Medical, LLC | $259.87 | 2024-2025 | Sucraid, Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $145.03 | 2019-2022 | |
| Janssen Scientific Affairs, LLC | $129.19 | 2023 | Stelara |
| Gilead Sciences, INC. | $110.69 | 2020-2021 | |
| Braintree Laboratories, INC. | $104.04 | 2019-2025 | Suflave, Sutab |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $101.22 | 2024-2025 | Xifaxan, Relistor, Trulance |
| Pfizer INC. | $94.41 | 2019-2025 | |
| Neuraxis, INC. | $87.25 | 2025 | |
| Aimmune Therapeutics, INC. | $71.44 | 2025 | Zenpep |
| Madrigal Pharmaceuticals | $69.05 | 2025 | Rezdiffra |
| Intercept Pharmaceuticals, INC. | $61.32 | 2025 | |
| Janssen Biotech, INC. | $59.75 | 2019-2025 | Tremfya |
| Celltrion USA INC. | $52.32 | 2025 | Vegzelma |
| Mauna Kea Technologies, INC. | $50.60 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $40.44 | 2023-2024 | Interstim |
| Regeneron Healthcare Solutions, INC. | $38.66 | 2025 | Dupixent |
| Ardelyx, INC. | $37.34 | 2025 | Ibsrela |
| Boston Scientific Corporation | $34.16 | 2025 | Axonics |
| Biocon Biologics INC | $24.69 | 2025 | Yesintek |
| Axonics, INC. | $22.90 | 2024 | Axonics |
| Novo Nordisk INC | $20.13 | 2025 | Wegovy |
| Ferring Pharmaceuticals INC. | $19.88 | 2025 | Rebyota |
| Genzyme Corporation | $18.16 | 2025 | |
| Exact Sciences Corporation | $16.64 | 2025 | Cologuard Collection Kit |
| Evoke Pharma, INC. | $16.29 | 2025 | |
| Phathom Pharmaceuticals, INC. | $13.63 | 2025 | Voquezna |
| Alfasigma USA, INC. | $12.48 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Parrack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.